CDK3-CYCLINE1 assay
Cyclin dependent kinase 3 (complex with cyclin E1)
Synonyms: cell division protein kinase 3
Family: CMGC
CDK3 is a cyclin dependent kinase, which is involved in G0/G1 and G1/S cell cycle transitions1. CDK3 is thought to act as a tumor promoter, due to its ability of promoting cell growth and transformation. Higher expression of CDK3 was reported in glioblastoma , skin cancer and colorectal cancer. However, it was shown that CDK3 overexpression plays an inhibitory effect of breast cancer motility1, meaning that CDK3 could exhibit different roles in different tumor stages and tumor types. Cyclin E1 is primarily known to bind CDK2, but it was also shown to bind and activate alternative Cdk partners such as Cdk32.
CDK3-CYCLINE1 kinase assay is run on mobility shift microfluidics platform (Caliper), which provides best in industry quality of data. We routinely run services associated with this kinase including: screening, profiling, dose-response studies and kinetic measurements. Please contact us for more information.
References:
1. Cao T, Xiao T, Huang G, Xu Y, Zhu JJ, Wang K, Ye W, Guan H, He J, Zheng D. CDK3, target of miR-4469, suppresses breast cancer metastasis via inhibiting Wnt/β-catenin pathway. Oncotarget. 2017 Oct 17;8(49):84917.
2. Geisen C, Möröy T. The oncogenic activity of cyclin E is not confined to Cdk2 activation alone but relies on several other, distinct functions of the protein. Journal of Biological Chemistry. 2002 Oct 18;277(42):39909-18.